P674: Blood thiopurine level, anti-TNF drug level and body composition parameters in inflammatory bowel diseases patients: a cross-sectional study in a Hungarian IBD centre
ECCO '19 Copenhagen
2019
P675: The relationship between gender, severity of disease, treatment type, and employment outcome in patients with inflammatory bowel disease in Israel
ECCO '19 Copenhagen
2019
P676: The impact to disease activity, iron and vitamin D deficiency on fatigue in IBD patients
ECCO '19 Copenhagen
2019
P677: Effect of late faecal loss of infliximab on treatment response of inflammatory bowel disease
ECCO '19 Copenhagen
2019
P679: Development of a novel auto-injector of subcutaneous CT-P13 infliximab: Phase I randomised, open-label, single-dose trial to compare the pharmacokinetics and safety to pre-filled syringe in healthy subjects
ECCO '19 Copenhagen
2019
P680: Long-term efficacy of ustekinumab with and without concomitant immunosuppressants for Crohn’s disease: results from IM-UNITI long-term extension through 2 years
ECCO '19 Copenhagen
2019
P681: Ustekinumab therapy induced clinically meaningful improvement and remission as measured by the Inflammatory Bowel Disease Questionnaire: Results from the phase 3 UNIFI induction and maintenance studies
ECCO '19 Copenhagen
2019
P682: GO-CARE: a prospective multi-centre observational study of golimumab effectiveness and quality of life in a real life UC patient population in Italy
ECCO '19 Copenhagen
2019
P683: Higher serum golimumab concentrations are significantly associated with combined clinical-biochemical remission during maintenance therapy: results from the GO-LEVEL study
ECCO '19 Copenhagen
2019
P686: Neither high infliximab maintenance doses nor high trough levels trigger skin side effects of the drug: a prospective cross-sectional study
ECCO '19 Copenhagen
2019
P687: Clinical remission demonstrated with oral ozanimod in the overall population and across multiple subgroups of patients with moderately to severely active ulcerative colitis in the TOUCHSTONE trial
ECCO '19 Copenhagen
2019
P688: Ustekinumab in resistant Crohn’s disease: 1-year UK IBD tertiary referral centre ‘real-world’ experience
ECCO '19 Copenhagen
2019
P689: The effect of nutritional therapy on bone mineral density and bone metabolism in paediatric Crohn’s disease
ECCO '19 Copenhagen
2019
P690: Comparative efficacy of vedolizumab and adalimumab as second-line therapy in ulcerative colitis patients previously treated with infliximab
ECCO '19 Copenhagen
2019
P691: Trends in diagnostic prevalence and treatment patterns of adult ulcerative colitis patients in the USA, 2007–2017
ECCO '19 Copenhagen
2019